Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912560 · ClinicalTrials.gov registry record · Phase 2
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Phase 2 study of Hypercholesterolemia and Dyslipidemia, sponsored by Catabasis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 14
- Study locations
NCT01912560 is a Phase 2 study of Hypercholesterolemia and Dyslipidemia that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 99 participants, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower). The trial reports 14 study locations across 9 states.
The verdict
NCT01912560, a Phase 2 study of Hypercholesterolemia and Dyslipidemia, has completed, sponsored by Catabasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with moderate hypertriglyceridemia and (2) fasting LDL-C levels in combination with a statin in patients with hypercholesterolemia who are on a statin.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Statin
- DRUG CAT-2003
Study Locations (14)
Florida
- - Jacksonville
- - Miami
- - Winter Park
Ohio
- - Cincinnati
- - Cincinnati
- - Cincinnati
North Carolina
- - Raleigh
- - Raleigh
Alabama
- - Muscle Shoals
California
- - Los Angeles
Kansas
- - Kansas City
Kentucky
- - Louisville
Maine
- - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01912560
The ClinicalTrials.gov registry entry for NCT01912560 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower). The listed sponsor is Catabasis Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hypercholesterolemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01912560 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Florida, Ohio, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01912560 about?
NCT01912560 is a clinical study titled "Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia". The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with moderate hypertriglyceridemia a...
What is the current status of trial NCT01912560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2013-07. Estimated completion is 2013-12.
What conditions does trial NCT01912560 study?
This clinical trial studies the following conditions: Hypercholesterolemia, Dyslipidemia, Hypertriglyceridemia.
What interventions are being tested in trial NCT01912560?
The interventions under investigation include: Placebo (DRUG), Statin (DRUG), CAT-2003 (DRUG).
Who is sponsoring clinical trial NCT01912560?
This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01912560 being conducted?
This trial has 14 study locations across Alabama, California, Florida, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
COMPLETED · Phase 2
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
COMPLETED · Phase 2
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
COMPLETED · Phase 2
-
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.